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Simple Summary: Earlier detection of ovarian cancer has the potential to improve patient outcomes,
including survival. However, determining which women presenting in primary care to refer for
specialist assessment and investigation is a clinical dilemma. In this study, we used routinely collected
English primary care data from 29,962 women with symptoms of possible ovarian cancer who were
tested for the ovarian cancer biomarker CA125. We developed diagnostic prediction models to
estimate the probability of the disease. A relatively simple model, consisting of age and CA125 level,
performed well for the identification of ovarian cancer. Including additional risk factors within the
model did not materially improve model performance. Following further validation, this model
could be used to help triage symptomatic women in primary care based on their risk of undiagnosed
ovarian cancer, identifying those at high risk for urgent specialist investigation and those at lower
(but still elevated) risk for non-urgent investigation or monitoring.
Abstract: CA125 is widely used as an initial investigation in women presenting with symptoms of
possible ovarian cancer. We sought to develop CA125-based diagnostic prediction models and to
explore potential implications of implementing model-based thresholds for further investigation in
primary care. This retrospective cohort study used routinely collected primary care and cancer reg-
istry data from symptomatic, CA125-tested women in England (2011–2014). A total of 29,962 women
were included, of whom 279 were diagnosed with ovarian cancer. Logistic regression was used to
develop two models to estimate ovarian cancer probability: Model 1 consisted of age and CA125 level;
Model 2 incorporated further risk factors. Model discrimination (AUC) was evaluated using 10-fold
cross-validation. The sensitivity and specificity of various model risk thresholds (≥1% to ≥3%) were
compared with that of the current CA125 cut-off (≥35 U/mL). Model 1 exhibited excellent discrimina-
tion (AUC: 0.94) on cross-validation. The inclusion of additional variables (Model 2) did not improve
performance. At a risk threshold of ≥1%, Model 1 exhibited greater sensitivity (86.4% vs. 78.5%) but
lower specificity (89.1% vs. 94.5%) than CA125 (≥35 U/mL). Applying the ≥1% model threshold
to the cohort in place of the current CA125 cut-off, 1 in every 74 additional women identified had
ovarian cancer. Following external validation, Model 1 could be used as part of a ‘risk-based triage’
system in which women at high risk of undiagnosed ovarian cancer are selected for urgent specialist
investigation, while women at ‘low risk but not no risk’ are offered non-urgent investigation or
interval CA125 re-testing. Such an approach has the potential to expedite ovarian cancer diagnosis,
but further research is needed to evaluate the clinical impact and health–economic implications.
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1. Introduction
In 2020, an estimated 313,959 women were diagnosed with ovarian cancer world-
wide [1]. Survival is highly dependent on the stage at diagnosis, with five-year survivals
of 93% and 13% for UK women diagnosed at stage I and IV, respectively [2]. Although
several large screening trials have been conducted, they have failed to demonstrate a long
term survival benefit [3,4]. In the absence of screening programs, the majority of women
with ovarian cancer are diagnosed after they present with symptoms [5,6]; thus, timely
diagnosis of these women may improve cancer outcomes.
In 2011, the National Institute for Health and Care Excellence (NICE) recommended
that women presenting to their General Practitioner (GP) with symptoms of possible
ovarian cancer in England, Wales, and Northern Ireland be tested for the serum biomarker
cancer antigen 125 (CA125) [7]. Further investigation with ultrasound was advocated if
CA125 levels were ≥35 U/mL. However, this threshold was not based on primary care
evidence. In primary care prior to diagnosis, 23% of women with ovarian cancer have
CA125 levels of less than 35 U/mL [8], and concerns have been raised over the potential
clinical impact of delayed diagnoses in this false-negative group [9]. In addition, even
if women have markedly elevated CA125 levels (indicating a very high likelihood of
undiagnosed ovarian cancer), they still must undergo GP-requested ultrasound before they
are eligible for an urgent (‘two-week wait’) cancer pathway referral to a specialist.
We recently developed a prediction model based on age and CA125 level in order
to estimate the probability of ovarian cancer in individual women undergoing testing
in primary care in England [8]. If implemented in clinical practice, such models would
allow women to be triaged using the risk of undiagnosed ovarian cancer so that those at
greatest risk undergo urgent specialist investigation, those at ‘low risk but not no risk’ are
monitored or undergo non-urgent investigation, and those at very low risk (the majority)
can be reassured. Such primary care evidenced risk-based triage strategies may reduce
diagnostic delay and thereby improve patient outcomes.
This study had three objectives. First, as previous studies have shown that a range
of patient risk factors and blood tests can help predict undiagnosed ovarian cancer [10],
we sought to develop a comprehensive diagnostic prediction model, making the best
use of variables routinely available in primary care. Second, we aimed to compare the
diagnostic performance of this model with that of a simpler model comprising age and
CA125. Third, we sought to explore the potential implications of implementing different
model risk thresholds on ovarian cancer detection in primary care.
2. Methods
This study is reported in accordance with transparent reporting of a multivariable
prediction model for individual prognosis or diagnosis (TRIPOD) guidelines. A completed
checklist is included (Table S1).
2.1. Data Source
We conducted a retrospective cohort study using linked data from the Clinical Prac-
tice Research Datalink (CPRD) GOLD, Hospital Episode Statistics Admitted Patient Care
dataset (HES APC), and the National Cancer Registration and Analysis Service (NCRAS).
The CPRD GOLD dataset contains anonymised, coded, primary care data including demo-
graphics, laboratory results, and symptoms for around 11 million patients and is broadly
representative of the UK population [11]. The HES APC dataset includes information about
hospital admissions and patient demographics, including ethnicity [12]. The NCRAS (the
English cancer registry) collects cancer registration data on patients, including detailed
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information on tumour topography and diagnosis date. The NCRAS obtains data from hos-
pitals, GP surgeries, and death certificates and reports a near 100% case ascertainment [13].
Linkage of CPRD and NCRAS data was performed at a patient level by a third party,
National Health Service (NHS) Digital [14]. The NCRAS only collects details of cancers
diagnosed in England, so the study was restricted to English general practices.
2.2. Participants
We identified women with a code for CA125 measurement in primary care between
1 May 2011 and 31 December 2014 and included all women who met the study criteria in
order to maximise sample size. We excluded women who were <18 years old or registered
at a GP practice not deemed ‘up-to-standard’ on data quality by CPRD on the date of their
first CA125 test during this period [11]. Women with a record of ovarian cancer in NCRAS
data on or before the CA125 test date were also excluded, as were women with a CA125
test in the 12 months before the first CA125 test during the study period. To maximise data
quality, only CA125 entries recorded in standard equivalent units of CA125 measurement
(U/mL, IU/mL, KU/L, KIU/L) were accepted, and CA125 values associated with spurious
laboratory cut-offs (245, 420, and 455 U/mL), or those where no cut-off was given, were
excluded. As our aim was to develop models for use in symptomatic women, and we
wished to develop a model that included symptom variables, we restricted the cohort to
those who had a recognised symptom of possible ovarian cancer recorded in the year prior
to CA125 testing. A code list was used to identify symptoms included in current NICE
guidelines on ovarian cancer detection [15]. Women with ascites or a palpable pelvic mass
recorded prior to CA125 testing were excluded, as these clinical signs have high positive
predictive values for ovarian cancer and warrant urgent referral to a specialist [15,16]. If
women had more than one CA125 test during the study period, only the first was used in
the analyses.
2.3. Outcome Definition
The primary outcome was a diagnosis of ovarian cancer, as recorded using Interna-
tional Classification of Disease (ICD)-10 codes in NCRAS data, in the 12 months following
initial CA125 testing. It was assumed that cancer diagnosed within 12 months of the initial
CA125 test was present at the time of CA125 testing. It is possible that incidental ovarian
cancers might arise and be diagnosed in the 12 months after testing or that it may take more
than 12 months following presentation for women to be diagnosed. We chose a period
of 12 months, which has been applied widely in previous studies [8,17–20], as a compro-
mise between minimising the inclusion of incidental ovarian cancers and maximising the
inclusion of relevant cancers.
Ovarian cancer was defined as an ovarian malignancy (C56), a fallopian tube malig-
nancy (C57.0), a peritoneal malignancy (C48.1, C48.2), or a neoplasm of uncertain behaviour
of the ovary (D39.1) [21,22].
2.4. Prediction Models
2.4.1. Candidate Variables
From the literature, we identified a list of candidate variables, which included
(1) established ovarian cancer risk/protective factors, (2) ovarian cancer symptoms, and
(3) blood tests. We focussed on variables that are well-recorded within GP records. While
all patients in this study had a symptom of possible ovarian cancer prior to CA125 testing,
previous research has demonstrated that these symptoms differ markedly in their predictive
value [19]. Symptoms were therefore included as variables to account for this. Routine
blood tests were included as recent studies have shown that both having a test performed
and the specific test level can be predictive of undiagnosed cancer in primary care [17,18,23].
The final list of candidate variables taken forward into data-driven selection procedures
was determined by the consensus of a multidisciplinary group consisting of GPs (GF, FMW,
and WH), a gynaecological oncologist (EJC), and a statistician (GA) (Table 1). Ethnicity
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was classified into 5 categories (White, Mixed, Black, Asian, and Other) in line with the
2001 census, using a pre-developed code list [24]. These were subsequently collapsed into
2 groups—“White” and “Other ethnicities”—as numbers in individual ethnic groups other
than White were small, and the risk of ovarian cancer is higher in people of White ethnicity
than Black and Asian ethnicity [25]. Recent research indicates that patients who have had
routine blood tests performed in primary care are at greater risk of undiagnosed cancer
(even if the test results are normal) when compared with those who have not had routine
blood tests performed [17]. Therefore, we included each routine blood test as a categorical
variable, with “no test” forming a category. Full details of variable preparation are included
in the supplementary material (Text S1).
Table 1. Candidate variables.
Variable Data Source Categorisation Variable Inclusion Time/Period
Risk/protective factors
Age [26] CPRD Continuous (years) On date of CA125 testing
Ethnicity [25,27] CPRDand HES Categorical: White Other ethnicities Most frequently recorded [24]
Height [28–31] CPRD Continuous (cm)
Most recent on/prior to CA125
test date recorded when
≥18 years old
BMI [28,32,33] CPRD Continuous (kg/m2)
Most recent on/in the 10 years
prior to CA125 test date
≥18 years old
Personal history breast




Binary for each symptom. Presence/absence of
abdominal/pelvic pain, appetite loss, bloating,
distension, change in bowel habit, fatigue,
urinary frequency/urgency, new irritable bowel
syndrome (≥50 years old), weight loss
12 months prior to CA125 testing
Blood biomarkers
CA125 [8] CPRD Continuous First valid CA125 level instudy period
Albumin [35] CPRD Categorical: Not tested <35 g/L ≥35 g/L
Most recent record on or in the
12 months prior to the CA125
test date
Haemoglobin [36] CPRD Categorical: Not tested <12 g/dL ≥12 g/d
Most recent record on or in the
12 months prior to the CA125
test date
Platelets [18] CPRD Categorical: Not tested <300 × 10
9/L
300–449 × 109/L ≥450 × 109/L
Most recent record on or in the
12 months prior to the CA125
test date
CRP [17,37] CPRD Categorical: Not tested <3 mg/L 3–9.99 mg/L≥10 mg/L
Most recent record on or in the
12 months prior to the CA125
test date
Abbreviations: BMI = body mass index, CRP = C-reactive protein, CPRD = Clinical Practice Research Datalink, CA125 = cancer antigen 125,
NCAS = National Cancer Registration and Analysis Service. Included citations provide further details on the association between candidate
variables and cancer risk. The choice of categories for categorical blood tests was based on standard references ranges and the literature.
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2.4.2. Model Derivation and Internal Validation
We developed two models. Model 1 was pre-specified and contained age and CA125 level
alone. Model 2 contained the most predictive variables selected from the list of candidates.
Prior to model derivation, continuous variables were mean-centred. BMI and CA125
level were right-skewed, so they were log-transformed. The relationships between log
CA125 and age with ovarian cancer were non-linear. To account for this, we generated
restricted cubic splines (5 knots) for log CA125 and age and included these in place of age
and log CA125 within the models [38]. The choice of 5 knots was pre-specified based on the
results of previous research, which used the study data to explore the relationship between
CA125 level, age, and ovarian cancer [8].
In order to derive Model 2, multivariate imputation by chained equation (MICE) [39]
was used to replace missing data on ethnicity, height, and body mass index (BMI). Twenty
imputations were performed. Following imputation, a logistic regression model containing
all candidate variables was fitted to estimate variable coefficients. Rubin’s rules were
used to combine the results across the imputed datasets [40]. Possible interaction between
age and log CA125 level was examined through the inclusion of an interaction term. We
examined 19 candidate variables with a total of 32 degrees of freedom (main effect and
non-main effect), giving 9 ‘Events Per Parameter’ (EPP). To select variables for Model 2, a
backward elimination approach was used in which the full model was fitted and the least
significant variable was removed; then the model was refitted and the process repeated
until all variables had a p value of ≤0.05. Variable coefficients were used as model weights.
To assess model discrimination, i.e., the ability of a model to distinguish those who
have a disease from those who do not have a disease, we calculated the area under the
receiver operating characteristic curve (AUC). Ten-fold cross-validation was performed
to assess for any optimism in model discrimination. To examine model calibration, i.e.,
agreement between model estimated outcomes and observed outcomes, we calculated the
calibration slope using 10-fold cross-validation. For Model 2, discrimination and calibration
were calculated for each imputed dataset, and Rubin’s rules were used to combine results
across the imputed datasets.
2.4.3. Model Thresholds
We devised thresholds to identify women with a ≥1%, ≥2%, and ≥3% probability
of undiagnosed ovarian cancer based on our models. The lowest threshold, ≥1%, was
selected, as patients have reported that they would opt for cancer investigations at this
risk level [41]. The highest threshold, ≥3%, was chosen to match the ‘risk threshold’ at
which NICE advocates urgent specialist cancer investigation or referral for symptomatic
primary care patients [15]. We applied these thresholds to the study cohort to calculate their
diagnostic accuracy (sensitivity, specificity, positive predictive value [PPV], and negative
predictive value [NPV]) for the detection of ovarian cancer within 12 months of CA125
testing. We compared these accuracy metrics with that of CA125 at its standard, NICE-
advocated cut-off (≥35U/mL) [7]. We also compared the accuracy of model thresholds to
that of CA125 cut-offs with equivalent sensitivities to determine whether using the models,
rather than just CA125-based cut-offs, improved accuracy.
All analyses were performed in Stata version 15.1. The user-written cvAUROC com-
mand was used to calculate cross-validation AUCs [42].
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3. Results
A total of 29,962 women met the inclusion criteria (Figure 1). Of these, 279 (0.9%) were
diagnosed with ovarian cancer in the 12 months following CA125 testing.
The baseline characteristics of the cohort are shown in Table 2. Missing data were
noted for ethnicity (n = 1234, 4.1%), height (n = 1721, 5.7%), and BMI (n = 2986, 10%).
The mean patient age was 55 years (range 18–101 years). The most common symptom
was abdominal/pelvic pain, recorded for 58.5% of women. The proportion of women
who had blood tests recorded (other than CA125) ranged from 66% for CRP to 94.5%
for haemoglobin.




Figure 1. Application of study criteria. “Invalid CA125 entry” = no CA125 value, no or incorrect units, and no upper 
threshold or spurious upper threshold. 
The baseline characteristics of the cohort are shown in Table 2. Missing data were 
noted for ethnicity (n = 1234, 4.1%), height (n = 1721, 5.7%), and BMI (n = 2986, 10%). The 
mean patient age was 55 years (range 18–101 years). The most common symptom was 
abdominal/pelvic pain, recorded for 58.5% of women. The proportion of women who had 
blood tests recorded (other than CA125) ranged from 66% for CRP to 94.5% for haemo-
globin. 
Table 2. Cohort baseline characteristics. 
Variable n = 29,962 
Risk/protective factors 
Age (years) Mean = 55 (SD: 15) 
Ethnicity: 
White n = 26,511 (88.5%) 
Other ethnicities * n = 2217 (7.4%) 
Height (cm) Mean = 162 (SD: 6.8) 
BMI (kg/m2) Median = 25.8 (IQR: 22.8–29.7) 
Personal history breast cancer n = 1168 (3.9%) 
Symptoms 
Abdominal/pelvic pain n = 17,538 (58.5%) 
Appetite loss n = 203 (0.7%) 
Bloating n = 5649 (18.9%) 
Distension n = 821 (2.7%) 
CIBH n = 5808 (19.4%) 
Fatigue n = 3968 (13.2%) 
Urinary frequency/urgency n = 1503 (5%) 
lication f t i i . “Invalid CA125 entry” = no CA125 value, no or i correct its,
threshold or spurious upper threshold.
Table 2. Cohort baseline characteristics.
V riable n = 29,962
Risk/protective factors
Age (years) Mean = 55 (SD: 15)
Ethnicity:
White n = 26,511 (88.5%)
Other ethnicities * n = 2217 (7.4%)
Height (cm) Mean = 162 (SD: 6.8)
BMI kg/m2) Median = 25.8 (IQR: 22.8–29.7)
Personal history breast cancer n = 1168 (3.9%)
Symptoms
Abdominal/pelvic pain n = 17,538 (58.5%)
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Table 2. Cont.
Variable n = 29,962
Appetite loss n = 203 (0.7%)
Bloating n = 5649 (18.9%)
Distension n = 821 (2.7%)
CIBH n = 5808 (19.4%)
Fatigue n = 3968 (13.2%)
Urinary frequency/urgency n = 1503 (5%)
≥50 years of age with new IBS n = 286 (1%)
Weight loss n = 1168 (3.9%)
Blood biomarkers
CA125 Median = 12 (IQR: 8–17)
Albumin:
Not tested n = 3723 (12.4%)
<35 g/L n = 834 (2.8%)
≥35 g/L n = 25,405 (84.8%)
Haemoglobin:
Not tested n = 1648 (5.5%)
<12 g/dL n = 3089 (10.3%)
≥12 g/dL n = 25,225 (84.2%)
Platelets:
Not tested n = 1679 (5.6%)
<300 × 109/L n = 20,442 (68.2%)
300–449 × 109/L n = 7314 (24.4%)
≥450 × 109/L n = 527 (1.8%)
CRP:
Not tested n = 13,181 (44%)
<3 mg/L n = 6907 (23.1%)
3–9.99 mg/L n = 7370 (24.6%)
≥10 mg/L n = 2504 (8.4%)
* Asian (n = 1117), Black (n = 562), Mixed (n = 160), and Other (n = 378). Abbreviations: SD = standard deviation,
IQR = interquartile range, IBS = irritable bowel syndrome, CA125 = cancer antigen 125, CRP = C-reactive protein.
3.1. Predictor Variables
The variables retained in Model 2 after backward elimination procedures were age,
ethnicity, BMI, height, abdominal/pelvic pain, distension, CA125 level, platelet level,
and albumin level. Coefficients and odds ratios for all variables are included in the
supplementary information (Table S2).
3.2. Model Discrimination and Calibration
The AUCs of Model 1 and 2, when directly calculated from the dataset (apparent
performance), were similar (Table 3). On cross-validation, the models had the same AUC
(0.935). There was little difference between apparent and cross-validation AUCs, indicating
that model overfitting/optimism was minimal. The AUC of CA125 alone, calculated
directly from the study cohort, was 0.932. Models 1 and 2 had calibration slopes close to 1,
indicating good calibration, but confidence intervals were wide.
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Table 3. Model discrimination and calibration.
Model Apparent AUC Cross-Validation AUC * Cross-Validation Calibration Slope (95% CI)
Model 1 0.938 0.935 1.01 (0.606–1.42)
Model 2 0.941 0.935 1.05 (0.673–1.42)
* Cross-validation ROC curves are included in Figures S1–S3.
3.3. Thresholds for Further Investigation
As the more parsimonious Model 1 exhibited the same cross-validation AUC and
similar calibration metrics to Model 2, the evaluation of thresholds for further investigation
focussed on Model 1. The diagnostic accuracies of Model 1 thresholds for the detection
of ovarian cancer within 12 months of CA125 testing are shown in Table 4. These were
compared against CA125 cut-offs with equivalent sensitives for ovarian cancer. At the ≥1%
probability threshold, the specificity of Model 1 was 3.1% higher than a CA125 cut-off with
the same sensitivity (≥23 U/mL), while there was a less marked difference at higher model
probability thresholds. At all model thresholds, the PPV was higher than that of CA125
cut-offs with equivalent sensitivities.
Table 4. Diagnostic accuracy metrics for a range of Model 1 thresholds and for CA125 at equivalent
sensitivities.




















































The potential implications of applying different model thresholds to the study cohort
of 29,962 women are illustrated in Figure 2. In comparison with the current CA125 cut-off,
applying a probability threshold of ≥1% would result in an additional 1622 women being
identified for further evaluation for ovarian cancer, of whom 22 (1.4%) would have ovarian
cancer; i.e., an additional 1 in every 74 women identified for further evaluation would have
ovarian cancer. Applying a ≥3% model probability threshold instead of the current CA125
cut-off would result in 706 fewer women being identified for further evaluation, of whom
8 (1.1%) would have ovarian cancer. Applying a 2% model threshold instead of the current
CA125 threshold would result in 58 fewer women being identified for further evaluation,
of whom none would have ovarian cancer.
Cancers 2021, 13, 2886 9 of 14
Cancers 2021, 13, x 8 of 14 
 
 
tion focussed on Model 1. The diagnostic accuracies of Model 1 thresholds for the detec-
tion of ovarian cancer within 12 months of CA125 testing are shown in Table 4. These were 
compared against CA125 cut-offs with equivalent sensitives for ovarian cancer. At the 
≥1% probability threshold, the specificity of Model 1 was 3.1% higher than a CA125 cut-
off with the same sensitivity (≥23 U/mL), while there was a less marked difference at 
higher model probability thresholds. At all model thresholds, the PPV was higher than 
that of CA125 cut-offs with equivalent sensitivities.  
Table 4. Diagnostic accuracy metrics for a range of Model 1 thresholds and for CA125 at equiva-
lent sensitivities. 


























































The potential implications of applying different model thresholds to the study cohort 
of 29,962 women are illustrated in Figure 2. In comparison with the current CA125 cut-
off, applying a probability threshold of ≥1% would result in an additional 1622 women 
being identified for further evaluation for ovarian cancer, of whom 22 (1.4%) would have 
ovarian cancer; i.e., an additional 1 in every 74 women identified for further evaluation 
would have ovarian cancer. Applying a ≥3% model probability threshold instead of the 
current CA125 cut-off would result in 706 fewer women being identified for further eval-
uation, of whom 8 (1.1%) would have ovarian cancer. Applying a 2% model threshold 
instead of the current CA125 threshold would result in 58 fewer women being identified 
for further evaluation, of whom none would have ovarian cancer. 
 
Figure 2. Implications of applying CA125 and model thresholds to the study cohort.
4. Discussion
A model consisting of CA125 and age alone demonstrated excellent discrimination
and calibration for the identification of ovarian cancer in women presenting to primary
care with relevant symptoms. Including additional baseline risk factors, symptom type,
and routine blood test results did not materially improve model performance. While the
model AUC was only slightly higher than that of CA125 alone, at a fixed sensitivity, Model
1 showed superior specificity and PPV at a range of thresholds. When a ≥1% probability
threshold was applied to our cohort, rather than the current CA125 cut-off (≥35 U/mL),
1 in 74 of the additional women identified by the model had ovarian cancer.
4.1. Strengths and Limitations
The dataset used in this study was a key strength. Information on candidate variables
was identified from a large, routinely collected primary care data source, which is broadly
representative of the UK general population, and outcome data were obtained from the
NCRAS (the English cancer registry), which is considered the gold standard source for
cancer diagnostic information for epidemiological research [13]. However, the use of
routinely collected data limited the candidate variables that we could include in our model.
For example, family history of ovarian cancer is an established risk factor for the disease
but was not included as a candidate variable as it is not routinely recorded in primary care
records. Including family history may have introduced bias, as a GP might be more likely
to ask about and record family history when there is a strong suspicion of ovarian cancer.
While CA125 testing is only indicated in women with relevant symptoms in UK
primary care, symptoms are not always coded within the GP notes; instead, they may be
recorded within the free text which is not available for research purposes [43]. In order
to include symptoms as predictor variables, we had to exclude 19,691 women who likely
had relevant symptoms that were simply not coded—this reduced sample size. Although
CPRD is one of the largest primary care datasets in the world, our sample size was limited
by available data on CA125 testing.
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The models developed in this study are intended to aid decision-making in women
selected by GPs for CA125 testing and, as such, were developed in an entirely CA125-tested
population. It is likely that CA125-tested women are at higher risk of ovarian cancer than
women with similar symptoms who were not selected for CA125 testing, so the models
may not be generalisable to the non-tested group.
We internally validated models—applying a cross-validation approach—to assess for
model optimism and found that this was minimal. However, external validation in an
independent dataset is warranted before the models are used in clinical practice.
4.2. Comparison with Existing Literature
In a recent systematic review, we did not identify any other diagnostic prediction
models that combined CA125 with symptom variables [10]. Existing primary care di-
agnostic prediction models, such as QCancer Ovarian [36], were developed in general
primary care populations (which included women with and without symptoms) with the
aim of identifying higher-risk women for tests such as CA125, whereas the models in this
study were developed within an entirely symptomatic CA125 tested population. Similarly,
secondary care models such as the Risk of Ovarian Malignancy Algorithm (ROMA) and the
Risk of Malignancy Index (RMI) are not comparable as they were developed in populations
in which all individuals were known to have a pelvic mass with the aim of distinguish-
ing between benign and malignant masses [44,45]. We have previously reported on the
diagnostic accuracy of CA125, as used in the primary care population, and have estimated
the probability of ovarian cancer based on patient age and CA125 level [8], but this is the
first study to evaluate the diagnostic accuracy of CA125 predicated models within the
symptomatic primary care population.
Baseline patient risk factors, routine blood test results, and the type of symptoms with
which patients present have previously been found to be predictive of ovarian cancer in
general practice [10] and so were included as candidate variables in this study. However,
our results indicate that, in symptomatic women undergoing CA125 testing, the CA125
level is the dominant predictor—the inclusion of other variables, with the exception of age,
does not materially improve model performance.
4.3. Implications for Research and Practice
In 2015, NICE recommended urgent cancer referral for symptomatic primary care
patients when the risk of a particular cancer reached 3% [15]. However, specific guidance
on ovarian cancer investigation and referral was not brought into line with this threshold.
NICE recommend that symptomatic women with CA125 levels ≥35 U/mL should be
referred by their GP for an ultrasound; only if the ultrasound shows evidence of possible
cancer do they qualify for an urgent cancer pathway referral. As primary care ultrasound
usually takes several weeks to be performed in England [46], this could delay ovarian cancer
diagnosis. The model developed in this study could be used to select women for urgent
cancer pathway referral, in line with the NICE 3% threshold, thereby helping to ensure
that those at higher risk of undiagnosed cancer receive prompt specialist investigation,
diagnosis and treatment.
We recently reported that women with false-negative CA125 results in English primary
care took twice as long to be diagnosed with ovarian cancer following testing as women
with abnormal CA125 results [20]. Such delays in diagnosis could have a detrimental effect
on patient outcomes, including morbidity and survival. Model 1 would allow women
with ‘low risk but not no risk’ of ovarian cancer to be identified and offered non-urgent
evaluation or interval re-assessment. Applying a ≥1% probability threshold (instead of
the current CA125 cut-off), this approach could help detect 1 extra ovarian cancer for
every 74 additional patients identified by the model for further evaluation. This evaluation
could involve re-testing for CA125, as most women who are retested in primary care prior
to diagnosis have rising CA125 levels [20], or a referral for a non-urgent transvaginal
ultrasound. An example of a risk-stratified approach using model thresholds is illustrated
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in Figure 3. As Model 1 is based solely on CA125 level and age, it could readily be
incorporated within laboratory computer systems, and the patient’s cancer probability
could be reported to the GP alongside the CA125 level.
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The recently published results from the United Kingdom Collaborative Trial of Ovar-
ian Cancer Screening (UKCTOCS) demonstrated that a multimodal ovarian cancer screen-
ing approach did not reduce mortality on long-term follow-up [3]. Given the time re-
quired to develop and evaluate new screening approaches, symptomatic detection is 
likely to remain the principal route for ovarian cancer diagnosis for some years, so opti-
mising the diagnostic pathway for symptomatic women remains important. Despite the 
earlier stage diagnosis of ovarian cancer in the multimodal screening arm of UKCTOCS, 
mortality was not reduced. Given this, when evaluating the clinical impact of new ap-
proaches that aim to expedite ovarian cancer diagnosis, such as the models presented 
within this study, survival should be considered alongside other outcomes.  
5. Conclusions 
A model consisting of age and CA125 level performs well for the detection of ovarian 
cancer in symptomatic women in English primary care. A risk-based triage system, in-
formed by this model, has the potential to expedite the diagnosis of ovarian cancer in 
those at high risk of undiagnosed ovarian cancer (through urgent specialist investigation) 
and ‘low risk but not no risk’ of ovarian cancer (through interval retesting or routine ul-
trasound). Further research is needed to evaluate the practical impact of implementing 
such an approach on patients and the healthcare system.  
Figure 3. Example risk-based triage system employing model probability thresholds.
Implementing a two-tier risk- tratified approach is likely to result in more non-urgent
investigation in primary care (‘low risk but not no risk’ women) nd more urgent cancer
referrals (higher risk women). Any such change in guidelines would require a full h alth
economic evaluation to assess he potential impact of such a strategy on the healthcare
service and on pati nts, as most of th se investig ted would ultimately not be diagn sed
w th ovarian ca cer. This evaluation would also be valuable i ensuring hat the most
appropri te model thresholds are chosen for use in clinical practice. The odel thresholds
evaluated ithin his study are of particular relevance o the hea thcare system in England.
H wever, following validat on in appropriate local datasets, our model could be us
to select women for further investigation for ovaria cancer in line with any regional or
national threshold.
In the current study, we have focussed on optimising the initial testing step within the
ovarian cancer diagnostic pathway. However, the timely diagnosis of cancer also depends
on the accuracy of subsequent testing steps, most notably ultrasound. Further research is
needed to ensure that the use of model-based risk thresholds improves the accuracy of the
diagnostic pathway as a whole.
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The recently published results from the United Kingdom Collaborative Trial of Ovar-
ian Cancer Screening (UKCTOCS) demonstrated that a multimodal ovarian cancer screen-
ing approach did not reduce mortality on long-term follow-up [3]. Given the time required
to develop and evaluate new screening approaches, symptomatic detection is likely to
remain the principal route for ovarian cancer diagnosis for some years, so optimising the
diagnostic pathway for symptomatic women remains important. Despite the earlier stage
diagnosis of ovarian cancer in the multimodal screening arm of UKCTOCS, mortality was
not reduced. Given this, when evaluating the clinical impact of new approaches that aim to
expedite ovarian cancer diagnosis, such as the models presented within this study, survival
should be considered alongside other outcomes.
5. Conclusions
A model consisting of age and CA125 level performs well for the detection of ovar-
ian cancer in symptomatic women in English primary care. A risk-based triage system,
informed by this model, has the potential to expedite the diagnosis of ovarian cancer in
those at high risk of undiagnosed ovarian cancer (through urgent specialist investigation)
and ‘low risk but not no risk’ of ovarian cancer (through interval retesting or routine
ultrasound). Further research is needed to evaluate the practical impact of implementing
such an approach on patients and the healthcare system.
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